These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
136 related articles for article (PubMed ID: 32076885)
21. A Novel Approach to Flurbiprofen Pulsatile Colonic Release: Formulation and Pharmacokinetics of Double-Compression-Coated Mini-Tablets. Vemula SK AAPS PharmSciTech; 2015 Dec; 16(6):1465-73. PubMed ID: 26017285 [TBL] [Abstract][Full Text] [Related]
22. Zero-Order Controlled Delivery of Gliclazide from Polyethylene Oxides Matrix Tables: In vitro and In vivo Evaluation. Wang L; Yang X; Di Y; Chen K; Wen H; Pan W Curr Drug Deliv; 2017; 14(1):136-144. PubMed ID: 27000027 [TBL] [Abstract][Full Text] [Related]
23. Controlled release formulation of tramadol hydrochloride using hydrophilic and hydrophobic matrix system. Tiwari SB; Murthy TK; Pai MR; Mehta PR; Chowdary PB AAPS PharmSciTech; 2003; 4(3):E31. PubMed ID: 14621963 [TBL] [Abstract][Full Text] [Related]
24. Interaction between fed gastric media (Ensure Plus®) and different hypromellose based caffeine controlled release tablets: comparison and mechanistic study of caffeine release in fed and fasted media versus water using the USP dissolution apparatus 3. Franek F; Holm P; Larsen F; Steffansen B Int J Pharm; 2014 Jan; 461(1-2):419-26. PubMed ID: 24342711 [TBL] [Abstract][Full Text] [Related]
25. Poly vinyl acetate and ammonio methacrylate copolymer as unconventional polymer blends increase the mechanical robustness of HPMC matrix tablets. Ali R; Dashevsky A; Bodmeier R Int J Pharm; 2017 Jan; 516(1-2):3-8. PubMed ID: 27818241 [TBL] [Abstract][Full Text] [Related]
26. Novel hydrophilic matrix system with non-uniform drug distribution for zero-order release kinetics. Cerea M; Maroni A; Palugan L; Bellini M; Foppoli A; Melocchi A; Zema L; Gazzaniga A J Control Release; 2018 Oct; 287():247-256. PubMed ID: 30171979 [TBL] [Abstract][Full Text] [Related]
27. Extended release of flurbiprofen from tromethamine-buffered HPMC hydrophilic matrix tablets. Pygall S; Kujawinski S; Timmins P; Melia C Pharm Dev Technol; 2018 Nov; 23(9):874-881. PubMed ID: 28298171 [TBL] [Abstract][Full Text] [Related]
28. Development of enteric-coated timed-release matrix tablets for colon targeting. Alvarez-Fuentes J; Fernández-Arévalo M; González-Rodríguez ML; Cirri M; Mura P J Drug Target; 2004; 12(9-10):607-12. PubMed ID: 15621686 [TBL] [Abstract][Full Text] [Related]
29. Investigation of a new pH-responsive nanoparticulate pore former for controlled release enteric coating with improved processability and stability. Chen K; Chang HHR; Shalviri A; Li J; Lugtu-Pe JA; Kane A; Wu XY Eur J Pharm Biopharm; 2017 Nov; 120():116-125. PubMed ID: 28887098 [TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetic properties of single-dose loratadine and ambroxol alone and combined in tablet formulations in healthy men. Villacampa J; Alcántar F; Rodríguez JM; Morales JM; Herrera J; Rosete R Clin Ther; 2003 Aug; 25(8):2225-32. PubMed ID: 14512130 [TBL] [Abstract][Full Text] [Related]
31. Subcoating with Kollidon VA 64 as water barrier in a new combined native dextran/HPMC-cetyl alcohol controlled release tablet. Castellanos Gil E; Iraizoz Colarte A; Lara Sampedro JL; Bataille B Eur J Pharm Biopharm; 2008 May; 69(1):303-11. PubMed ID: 18053697 [TBL] [Abstract][Full Text] [Related]
32. Oral controlled release formulations of rifampicin. Part II: Effect of formulation variables and process parameters on in vitro release. Hiremath PS; Saha RN Drug Deliv; 2008; 15(3):159-68. PubMed ID: 18379928 [TBL] [Abstract][Full Text] [Related]
33. Design and Evaluation of Hydrophilic Matrix System for pH-Independent Sustained Release of Weakly Acidic Poorly Soluble Drug. Huang J; Lin H; Peng B; Huang Q; Shuai F; Xie Y AAPS PharmSciTech; 2018 Jul; 19(5):2144-2154. PubMed ID: 29714000 [TBL] [Abstract][Full Text] [Related]
34. Quality by Design Empowered Development and Optimisation of Time-Controlled Pulsatile Release Platform Formulation Employing Compression Coating Technology. Patadia R; Vora C; Mittal K; Mashru RC AAPS PharmSciTech; 2017 May; 18(4):1213-1227. PubMed ID: 27460936 [TBL] [Abstract][Full Text] [Related]
35. Drug release-modulating mechanism of hydrophilic hydroxypropylmethylcellulose matrix tablets: distribution of atoms and carrier and texture analysis. Park JB; Lim J; Kang CY; Lee BJ Curr Drug Deliv; 2013 Dec; 10(6):732-41. PubMed ID: 23855499 [TBL] [Abstract][Full Text] [Related]
36. Oral sustained delivery of ambroxol from in situ-gelling pectin formulations. Kubo W; Miyazaki S; Dairaku M; Togashi M; Mikami R; Attwood D Int J Pharm; 2004 Mar; 271(1-2):233-40. PubMed ID: 15129990 [TBL] [Abstract][Full Text] [Related]
37. Design and evaluation of a zero-order controlled release system based on pre-hydrated constant release area prepared by compression coating technology. Wang Q; Jiao J; Cai Q; Wang Q; Zhou W Pharm Dev Technol; 2021 Dec; 26(10):1120-1129. PubMed ID: 34698603 [TBL] [Abstract][Full Text] [Related]
38. Aqueous coating dispersion (pseudolatex) of zein improves formulation of sustained-release tablets containing very water-soluble drug. Li XN; Guo HX; Heinamaki J J Colloid Interface Sci; 2010 May; 345(1):46-53. PubMed ID: 20129615 [TBL] [Abstract][Full Text] [Related]
39. An oral controlled release system for ambroxol hydrochloride containing a wax and a water insoluble polymer. Chi N; Guo JH; Zhang Y; Zhang W; Tang X Pharm Dev Technol; 2010; 15(1):97-104. PubMed ID: 19671037 [TBL] [Abstract][Full Text] [Related]
40. Development and release mechanism of diltiazem HCl prolonged release matrix tablets. Boyapally H; Nukala RK; Douroumis D Drug Deliv; 2009 Feb; 16(2):67-74. PubMed ID: 19267297 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]